Photo Kate Rochlin, Ph.D., President & COO NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin has served as IN8bio’s Chief Operating Officer since December 2021, following her tenure as Vice President and ...

Summary of IN8bio Conference Call - February 05, 2026 Company Overview - **Company**: IN8bio (NasdaqGM:INAB) - **Focus**: Development of cellular therapies using gamma delta T cells - **Key Personnel**: William Ho (CEO), Dr. Larry Lamb (Chief Scientific Officer) [1][2] Core Programs and Pipeline - **Ongoing Programs**: - **INB-100**: Allogeneic cell therapy for leukemia patients undergoing transplantation, currently enrolling an expansion cohort with updated phase one data expected by year-end [3] - **INB-619**: T cell engager platform targeting CD19 for both oncology and autoimmune diseases [3] - **INB-200 and INB-400**: Genetically modified gamma-delta T cell programs targeting solid tumors, particularly glioblastoma [3][4] Glioblastoma Treatment Insights - **Mechanism of Action**: Targets the DNA damage response (DDR) pathway, which is fundamental to all cells, making it potentially applicable to various solid tumors [33] - **Clinical Trial Results**: - Patients treated with INB-200 and INB-400 showed a median progression-free survival (PFS) of 13 months, compared to 6.6 months in the control group [14] - Overall survival (OS) for treated patients reached 17.2 months, with some patients remaining progression-free for over 4 years [15][47] - No major toxicity signals or adverse events reported [11] T Cell Engager Platform - **INB-619**: A unique CD19 targeting T cell engager designed to minimize cytokine release syndrome (CRS) while effectively depleting B cells [22][27] - **Comparative Efficacy**: INB-619 demonstrated comparable or superior potency to existing B-cell depleters like Amgen's blinatumomab and Roche's mosunitumab, with a significantly wider therapeutic window [26][27] Financial and Operational Updates - **Recent Financing**: Raised $20.1 million led by Coastlands Capital, with participation from Franklin Templeton and other investors, providing runway through 2027 [28][50] - **Upcoming Milestones**: - Public peer-reviewed publication of glioblastoma data - FDA guidance on regulatory path for glioblastoma program - Mouse data for INB-619 expected by late summer [53] Additional Insights - **Market Positioning**: IN8bio has chosen not to pursue autoimmune diseases with cell therapies, focusing instead on oncology due to concerns about the safety and efficacy of existing treatments in that area [20] - **Histopathology Findings**: Analysis of treated patients showed significant infiltration of gamma-delta T cells, indicating effective targeting of tumors [19] Conclusion - IN8bio is making significant strides in the development of innovative therapies for glioblastoma and leukemia, with promising clinical results and a solid financial foundation to support ongoing research and development efforts [29]

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity ConferenceDate: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual Inve ...

Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocolMedian overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several patients who remain progression-free for multiple years (1.4 – 4.6 years) compared to only 13.2 months for SOC (+30.3%)Treatment remain ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - IN8bio has secured a private placement financing of approximately $40.2 million to advance its γδ T cell therapies, particularly focusing on the INB-619 product candidate for cancer and autoimmune diseases [2][4]. Financing Details - The financing includes an initial closing of about $20.1 million, with the potential for an additional $20.1 million based on milestone achievements [1][4]. - The initial tranche involves the sale of 5,127,029 shares of common stock at $1.38 per share and pre-funded warrants for up to 9,452,677 shares at a price of $1.3799 [4]. - The financing is led by Coastlands Capital, with participation from other investors such as Stonepine Capital Management and 683 Capital Partners [3][4]. Use of Proceeds - The net proceeds will fund IND enabling studies for INB-619, with early animal model data expected for discussions with the FDA in 2026 and potential IND submission in 2027 [5]. - A portion of the funds will also support the submission of data from the INB-200 and INB-400 Phase 1 and Phase 2 clinical programs for glioblastoma to the FDA [5]. Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing γδ T cell therapies for unmet medical needs, particularly in oncology and autoimmune diseases [9][10]. - The lead program, INB-100, targets acute myeloid leukemia, while INB-200 and INB-400 focus on glioblastoma [10].

Clinical Trials and Product Development - The Phase 1 trial of INB-100 demonstrated 100% complete remission (CR) in acute myeloid leukemia (AML) patients, with a median follow-up of 20.1 months, and 100% progression-free survival (PFS) and overall survival (OS) rates at one year post-transplant[99] - INB-200 showed a median PFS of 16.1 months in patients receiving repeated doses, representing a 133% increase over the expected 6.9 months for standard-of-care, with preliminary data indicating improved outcomes compared to historical controls[101] - INB-619 effectively eliminated CD19+ B cells in patients with Systemic Lupus Erythematosus (SLE), demonstrating minimal release of inflammatory cytokines associated with cytokine release syndrome (CRS)[105] - INB-400's Phase 2 trial enrollment was suspended in September 2024 to conserve cash resources, while preliminary data from additional centers reported a median PFS of 10.8 months[102] - The company plans to complete enrollment of the INB-100 expansion cohort by year-end 2025 or early 2026, with long-term follow-up results anticipated in 2026[100] - INB-600, a proprietary T cell engager platform, aims to enhance immune responses against solid tumors and autoimmune diseases by selectively activating gamma-delta T cells[103] - The company introduced INB-300 and INB-500, targeting both solid and liquid tumors, with INB-500 focusing on producing gamma-delta T cells from induced pluripotent stem cells (iPSCs)[110] - The company received Orphan Drug Designation from the FDA for INB-400, covering a broad range of malignant glioma indications, including relapsed and newly diagnosed GBM[102] Financial Performance and Funding - The company has not generated any revenue since its inception in 2016 and has primarily funded operations through equity sales, including an initial public offering (IPO) and private placements[114] - As of September 30, 2025, the company has cash of $10.7 million, which is not anticipated to fund projected operating expenses for at least 12 months, raising substantial doubt about its ability to continue as a going concern[115] - The company expects to incur additional losses in the future as it advances product candidates through clinical trials and expands its portfolio[115] - The company has raised an aggregate of $143.0 million from the sale of equity and equity-linked securities through September 30, 2025[134] - Interest income for the three months ended September 30, 2025, was $0.1 million, compared to $0 million in the same period in 2024[129] - The company plans to raise additional capital through equity and/or debt offerings and strategic collaborations to support product development[116] - Cash used in operating activities was $10.6 million for the nine months ended September 30, 2025, primarily due to a net loss of $14.5 million[152] - Cash provided by financing activities was $10.1 million during the nine months ended September 30, 2025, mainly from $8.4 million in net proceeds from the ATM program[156] - The company has not generated any product revenue since inception and does not expect to do so in the foreseeable future[145] - The company anticipates substantial increases in expenses related to ongoing activities, particularly in clinical trials and product development[142] Expenses and Cost Management - Research and development expenses for the three months ended September 30, 2025, were $2.1 million, a decrease of $1.2 million from $3.3 million in the same period in 2024[126] - General and administrative expenses for the three months ended September 30, 2025, were $1.9 million, down from $2.7 million in the prior year, reflecting a decrease in personnel-related costs[128] - Total operating expenses for the nine months ended September 30, 2025, were $14.8 million, a decrease of $9.6 million from $24.4 million in the same period in 2024[130] - Research and development expenses for the nine months ended September 30, 2025, were $7.6 million, down from $13.4 million in the prior year, primarily due to a decrease in personnel-related costs[131] Stock and Warrants - The company may receive up to $12.1 million from the exercise of outstanding common stock warrants, although there is no assurance of receiving these proceeds[116] - As of September 30, 2025, the company had issued and outstanding 248,382 pre-funded warrants, 129,296 Series A warrants, 303,574 Series B warrants, and 997,638 Series C warrants[138] - The company expects to receive up to $8.1 million from the exercise of Series C warrants and pre-funded warrants, and up to $4.1 million from Series B warrants, contingent on full cash exercise[139] - The company sold 511,057 shares under the ATM program in the three months ended September 30, 2025, generating net proceeds of approximately $1.1 million, and 1,815,346 shares in the nine months ended September 30, 2025, generating net proceeds of approximately $8.5 million[140] Regulatory and Compliance - The company adopted ASU 2023-07 effective January 1, 2025, which requires public entities to disclose significant expenses and other segment items on an interim and annual basis[164] - The company is evaluating the impact of adopting ASU 2023-09, effective for fiscal years beginning after December 15, 2024, with early adoption permitted[165] - The company qualifies as an emerging growth company (EGC) and may take advantage of reduced disclosure requirements until December 31, 2026[166] - The company will cease to be an EGC if it exceeds $1.235 billion in annual revenue or $700 million in market value of stock held by non-affiliates[167] - The company has elected not to "opt out" of the extended transition period for complying with new accounting standards, delaying adoption until standards apply to private companies[168] - The company is classified as a smaller reporting company and may continue to be so until the market value of stock held by non-affiliates is less than $250 million[169] - As a smaller reporting company, the company may present only the two most recent fiscal years of audited financial statements in its Annual Report[172] - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company[173]

Core Insights - IN8bio, Inc. has announced the addition of The Ohio State University as a new clinical site for its ongoing Phase 1 trial of INB-100, a gamma-delta T cell therapy for leukemia patients undergoing haploidentical stem cell transplantation [1][2] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases [4] - The lead program, INB-100, targets acute myeloid leukemia and evaluates haplo-matched allogeneic gamma-delta T cells administered post-hematopoietic stem cell transplant [4] Clinical Trial Details - The Phase 1 trial aims to assess the safety, durability, and anti-leukemic activity of INB-100 in the post-transplant setting [3] - Principal Investigator Dr. Joseph P. McGuirk leads the trial, which has shown encouraging long-term survival outcomes compared to historical data [3] - The trial has reported immune reconstitution, including the expansion and persistence of INB-100 gamma-delta T cells up to one year post-treatment, and an absence of severe graft-versus-host disease [3] Strategic Partnerships - The collaboration with The Ohio State University reflects strong interest in INB-100 and aims to accelerate enrollment in the Phase 1 trial [2] - The trial is expected to provide follow-up data next year, with multiple patients showing long-term leukemic remissions beyond four to five years [3]

Core Insights - IN8bio, Inc. presented new preclinical data for its γδ T cell engager program, INB-619, at the 2025 ACR Convergence Meeting, highlighting its potential in treating cancer and autoimmune diseases [1][2] Preclinical Data - INB-619 demonstrated complete elimination of B cells in preclinical SLE donor models, showing efficacy comparable to FDA-approved CD19 and CD20 engagers like blinatumomab and mosunetuzumab [2][8] - The compound exhibited minimal secretion of adverse cytokines, such as IL-6, at significantly lower concentrations than currently marketed compounds [2][6] Mechanism and Safety Profile - INB-619's design allows for higher doses and deeper B cell depletion, potentially leading to an immune reset not observed with other protein engagers [3][4] - The therapy selectively expanded γδ T cells without activating CD4+ or CD8+ αβ T cells, indicating a potentially improved safety and tolerability profile [3][4] Unique Properties - INB-619 is a first-in-class, CD19-targeted, pan-γδ T cell engager that activates and expands both V-delta-1 and V-delta-2 T cell subsets, leading to effective B cell depletion [4][8] - Unlike conventional T cell engagers, INB-619 does not engage the CD3 receptor, significantly reducing the risk of toxicities such as cytokine release syndrome and neurotoxicity [5][6] Clinical Implications - The results suggest that INB-619 could transform the treatment landscape for autoimmune diseases by safely eliminating pathogenic B cells and driving immune reset [6][8] - The data indicated robust, dose-dependent B cell killing and γδ T cell expansion, maintaining a favorable cytokine profile consistent with γδ T cell biology [6][8] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing γδ T cell therapies for unmet medical needs, with additional programs targeting acute myeloid leukemia and glioblastoma [7]

Clinical Trial Results - INB-100 demonstrated 100% complete remission (CR) in acute myeloid leukemia (AML) patients with a median follow-up of 20.1 months, surpassing real-world control groups with 67.8% progression-free survival (PFS) and 74.7% overall survival (OS) at one year [100]. - INB-200 achieved a median PFS of 16.1 months, a 133% increase over the expected 6.9 months for standard-of-care, with 40% of patients remaining progression-free for over 18 months [101][108]. - INB-619 showed complete targeted depletion of harmful B cells in lupus samples without significant inflammatory cytokines, indicating a safer immunotherapy alternative [105][108]. - The company is currently enrolling an expansion cohort for INB-100, targeting up to 15 additional patients to confirm improvements in relapse-free and OS [100]. - INB-600, a proprietary T cell engager platform, aims to enhance anti-tumor responses while minimizing risks of cytokine release syndrome (CRS) [103]. - The company presented preclinical data for INB-300, demonstrating proof-of-concept against leukemia antigen targets CD33 and CD123, indicating potential for distinguishing tumor from healthy tissue [107]. - As of May 31, 2025, patients receiving repeated doses of INB-200 showed a median PFS of 10.8 months in a multi-center trial, with additional data expected later this year [102]. - The company expects to present further preclinical data for the INB-600 platform in the second half of 2025, indicating ongoing development and potential applications [106]. Financial Performance - As of June 30, 2025, the company has $13.2 million in cash, which is not anticipated to fund projected operating expenses for at least 12 months, raising substantial doubt about its ability to continue as a going concern [111]. - Total operating expenses for the three months ended June 30, 2025, were $5.2 million, a decrease of $3.5 million compared to $8.7 million for the same period in 2024 [123]. - Research and development expenses decreased to $2.5 million for the three months ended June 30, 2025, from $5.2 million in the prior year, primarily due to a $1.3 million decrease in personnel-related costs [124]. - General and administrative expenses were $2.7 million for the three months ended June 30, 2025, down from $3.5 million in the same period in 2024, reflecting cost savings in personnel and professional services [125]. - The company has not generated any revenue since inception and does not expect to do so in the foreseeable future [116]. - The company expects to incur additional losses as it advances product candidates through clinical trials and expands its portfolio [111]. - Interest income for the three months ended June 30, 2025, was $0.1 million, an increase of $0.05 million compared to the same period in 2024 [126]. - For the six months ended June 30, 2025, total operating expenses were $10.9 million, a decrease of $6.5 million from $17.3 million in 2024 [127]. - Research and development expenses decreased to $5.5 million for the six months ended June 30, 2025, down from $10.1 million in the prior year, a reduction of $4.6 million [128]. - General and administrative expenses were $5.4 million for the six months ended June 30, 2025, compared to $7.3 million in the prior year, reflecting a decrease of $1.9 million [129]. - As of June 30, 2025, the company had cash of $13.2 million, which is expected to fund operations into June 2026 [132]. - The company raised an aggregate of $139.6 million from the sale of equity and equity-linked securities through June 30, 2025 [131]. - Net cash used in operating activities was $7.0 million for the six months ended June 30, 2025, primarily due to a net loss of $10.6 million [150]. - The company sold 1,304,289 shares under the ATM program during the six months ended June 30, 2025, resulting in net proceeds of approximately $7.4 million [139]. - The company expects substantial increases in expenses contingent on additional funding for ongoing activities, particularly for clinical trials [140]. - As of June 30, 2025, the company had fixed lease payment obligations of $3.8 million, with $1.4 million payable within 12 months [147]. - The company has not generated any product revenue and has incurred net losses and negative cash flows from operations since inception [143]. - The company may receive up to $9.8 million from the exercise of outstanding warrants, assuming full cash exercise [136]. - Cash used in operating activities was $14.0 million for the six months ended June 30, 2024, primarily due to a net loss of $17.2 million [151]. - Non-cash charges included $2.4 million in stock-based compensation, reflecting increased employee headcount [152]. - Cash used in investing activities was $0.2 million during the six months ended June 30, 2024, mainly for property and equipment purchases [153]. - Cash provided by financing activities was $3.1 million for the six months ended June 30, 2024, primarily from the issuance of common stock [155]. - Cash provided by financing activities was $9.2 million for the six months ended June 30, 2025, primarily from the ATM program [154]. Corporate Governance and Compliance - The company adopted ASU 2023-07 effective January 1, 2025, which requires enhanced disclosures about reportable segments [163]. - The company qualifies as an emerging growth company (EGC) and can take advantage of reduced disclosure requirements until December 31, 2026 [165]. - The company is also classified as a smaller reporting company, allowing it to present only the two most recent fiscal years of audited financial statements [170]. - Research and development expenses include salaries, stock-based compensation, and lab supplies, with all costs expensed as incurred [159]. - The company has not experienced material adjustments to prior estimates of accrued research and development expenses [161]. Operational Adjustments - The company plans to implement cash preservation measures, including workforce reduction and prioritization of its pipeline, to address liquidity needs [112]. - The company executed a one-for-thirty reverse stock split on June 5, 2025, adjusting the per share exercise price and number of shares issuable under outstanding options and warrants [114].